Announced
Completed
Existing investors led a €25m in Oncomatryx.
Synopsis
Existing investors led a €25m in Oncomatryx, a Spanish biopharmaceutical company specializing in antibody-drug conjugates (ADCs) targeting the tumor microenvironment, with participation from Centro para el Desarrollo Tecnológico y la Innovación (CDTI).
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Seller Team (2)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite